
Opinion|Videos|December 23, 2024
Navigating HER2 Heterogeneity: Precision Pathways in Breast Cancer Treatment
A panelist discusses how differences in HER2-positive, HER2-low, and HER2-negative status impact clinical decision-making.
Advertisement
Episodes in this series

Now Playing
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Poherdy, First Biosimilar to Perjeta, For HER2 Breast Cancer Indications
2
Higher Ultra-Processed Food Intake Linked to Increased Prediabetes Risk in Young Adults
3
Pharmacist Spotlight: Amir Masood, PharmD
4
Ziftomenib Receives FDA Approval for Acute Myeloid Leukemia With NPM1 Mutations
5

















































































































































































































